Working to Eradicate Gynecologic Cancers

Kevin Frick, PhD

Professor
Johns Hopkins Bloomberg School of Public Health
624 N. Broadway, Rm 606
Baltimore, MD
USA 21205

Papers:
364 - Poster Session B Is paclitaxel a more cost-effective choice for maintenance therapy than bevacizumab in the primary treatment of advanced ovarian cancer?